# Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury

> **NCT02975271** · PHASE2 · TERMINATED · sponsor: **Vyne Therapeutics Inc.** · enrollment: 1 (actual)

## Conditions studied

- Pruritus
- Burns

## Interventions

- **DRUG:** Serlopitant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02975271
- **Lead sponsor:** Vyne Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-11
- **Primary completion:** 2017-01-17
- **Final completion:** 2017-01-17
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Business Reasons
- **Last updated:** 2021-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02975271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02975271, "Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02975271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*